Compare Meta Platforms Inc (META) vs Novavax Inc (NVAX) Price & Performance

META stock trades at $653.33, up 1.13% in the last session, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $10.44 versus $6.70 expected. Revenue grew to $201.0 billion in 2025, with a net income margin of 30.08%. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, driving positive sentiment.

Outlook remains positive with a consensus price target of $817.32, implying 25% upside. Key opportunities include AI monetization and sustained revenue growth, while risks involve regulatory lawsuits and high capital expenditures. Analyst consensus is strongly bullish with 79% buy ratings, but investors should monitor legal developments and competitive pressures in the social media and AI sectors.

Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.

The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.